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Background. Genetic testing for cancer susceptibility is an emerging technology in medicine. This study
assessed the knowledge, attitudes and professional behavior of Italian physicians regarding the use of predic-
tive genetic tests for breast and colorectal cancer, including the BRCA1/2 and APC tests.
Methods. A cross-sectional survey of a random sample of Italian physicians was performed in 2010
through a self-administered questionnaire.
Results. A response rate of 69.6% (1079 questionnaires) was achieved. A signiﬁcant lack of knowledge was
detected, particularly for APC testing. Less than half of the physicians agreed on the importance of efﬁcacy
and cost-effectiveness evidence in the selection of predictive genetic tests to be offered to the patients. Mul-
tiple logistic regression analyses showed that education had a positive inﬂuence on knowledge, attitudes and,
to a lesser extent, professional use. The factor most strongly related to the physicians' use of genetic testing
was patients requests for breast (odds ratio = 12.65; 95% conﬁdence interval 7.77–20.59) or colorectal can-
cer tests (odds ratio = 7.02; 95% conﬁdence interval 3.61–13.64). A high level of interest for speciﬁc training
was reported by almost all physicians surveyed.
Conclusions. Targeted educational programs are needed to improve the expertise of physicians, and, ulti-
mately, to enhance the appropriate use of genetic tests in clinical practice.© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
Among predictive genetic testing for complex diseases, tests for
breast and colorectal cancer, if used appropriately, have been demon-
strated to be efﬁcacious and cost-effective (Becker et al., 2011). Phy-
sicians play a key role in properly incorporating emerging DNA
technologies in health care (Anon, 2011; Feero and Green, 2011) be-
cause they have to be adept not only at using genetic tests in clinical
care but also in explaining the test results and their limitations to
patients.
Calls for enhanced genomic education for health care professionals
predate the completion of the Human Genome Project (Collins, 1997).. Marzuillo),
icatt.it (S. Boccia),
@gmail.com (E. D’Andrea),
a1.it (A. Boccia),
nc. Open access under CC BY-NC-ND liDespite this, several surveys performed in the U.S., Europe and Canada
show that doctors are not prepared for the increasing use of genetics
in clinical care (Acton et al., 2000; Batra et al., 2002; Bellcross et al.,
2011; Bethea et al., 2008; Burke et al., 2009; Carroll et al., 2008;
Escher and Sappino, 2000; Freedman et al., 2003; Klitzman et al.,
2012; Mehnert et al., 2003; Nippert et al., 2011; Pichert et al., 2003;
Sabatino et al., 2007; Shields et al., 2008; Sifri et al., 2003; Toiviainen
and Hemminki, 2001; Trivers et al., 2011; Van Riel et al., 2010;
Welkenhuysen and Evers-Kiebooms, 2002; White et al., 2008;
Wideroff et al., 2003; Wideroff et al., 2005; Wilkins-Haug et al.,
2000). Many physicians do not have any speciﬁc education and the
vast majority does not feel they have the needed training and knowl-
edge for the appropriate use of genetic testing to guide prevention or
treatment decisions (Anon, 2011; Feero and Green, 2011). Recent
surveys tested the effectiveness of educational interventions at
improving the competency of doctors in this ﬁeld (Bethea et al.,
2008; Carroll et al., 2008, 2009; Drury et al., 2007).
The present study assessed the knowledge, attitudes, and profes-
sional behavior of a random sample of Italian physicians toward the
use of predictive genetic testing for breast and colorectal cancer,
particularly the BRCA 1/2 and APC tests. A variety of determinants
were explored, including education.cense.
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In 2010, a self-administered anonymous questionnaire was e-mailed to
1670 physicians randomly selected from the registers of the Board of Physi-
cians of Provinces of Rome and Florence. The physicians were chosen
irrespective of their specialty because this information is not recorded in the
registers. The online questionnaire could only be answered once. Second
and third questionnaires were e-mailed to non-responders 3 and 6 months
after the initial e-mail. To maximize the response rate, telephone calls were
placed before each of the follow-up mailings. A total of 107 physicians could
not be contacted by telephone because their numbers were not available.
The questionnaire (a copy is available upon request) comprised a series of
questions designed to assess the following: i) the physicians' demographics
and personal and professional characteristics; ii) their knowledge, attitudes,
and professional use of genetic tests for breast and colorectal cancer; iii) their
self-estimated level of knowledge and training needs.
Knowledge about predictive genetic tests for cancer was investigated
through six questions using a three-point options Likert scale (“agree”, “uncer-
tain,” and “disagree”) [see Table 2(A) for the actual items used]. Additional four
multiple-choice questionswere designed to evaluate the physicians' knowledge
concerning the prevalence of hereditary breast cancer and inherited forms
of colorectal cancer and the penetrance of BRCA1/BRCA2 and APC mutations
[see Table 2(B)]. A Likert three-point scale was used to assess the physicians'
attitudes through seven questions (see Table 4). In the behavior section,
physicians were asked if they had administered genetic tests for breast and co-
lorectal cancer to their patients during the previous 2 years and queried about
the importance of genetic counseling and collecting information about the fam-
ily and personal history of cancer. The ﬁnal set of questions required the physi-
cians to assess their own level of knowledge according to a four-answer format
(“inadequate,” “sufﬁcient,” “good,” and “excellent”) and their need for training
(“yes/no” answer).
Extensive pre-administration piloting was conducted with a convenience
sample of physicians similar to the study population. A clear need to slim
down the questionnaire emerged. Therefore, only questions concerning APC
mutationswere included among the knowledge items concerning the inherited
forms of colorectal cancer, thus excluding questions regarding gene mutations
associated with the Lynch syndrome. Other minor revisions included changes
to the questionnaire item wording and format.Statistical analysis
Multiple logistic regression analysis was performed. Five models
were built to identify the predictors of physicians knowledge of
predictive genetic testing for breast and colorectal cancer (Models 1
and 2), attitudes (Model 3), and professional use of predictive genetic
tests for breast and colorectal cancer (Models 4 and 5). For purposes
of analyses, the outcome variables “knowledge” and “attitudes” in
Models 1–3, originally consisting of multiple categories, were collapsed
into two levels. In brief, for the variable knowledge physicians were di-
vided in those who agreed with all correct responses versus all others,
while for attitudes responders were grouped into those who showed a
positive attitude in at least 70% of the questions versus all others (see
Table 3 for the details of dichotomization). The following physician
characteristics were initially tested in all models as predictor variables:
location; gender; age; exposure to cancer genetic testing during gradu-
ate/postgraduate courses; attendance to postgraduate epidemiology
and Evidence BasedMedicine (EBM) courses; knowledge of the English
language; internet access in the workplace; hours per week dedicated
to continuingmedical education; the average number of patients treat-
ed in a typical week; patient requests for genetic tests in the previous
year; the presence of genetic testing laboratories in the geographical
area of professional activity; and a personal or family history of breast
or colorectal cancer. The variable “adequate knowledge” was also in-
cluded in the model concerning attitudes, and the variables “adequate
knowledge” and “positive attitudes” were included in the models
concerning the professional use of predictive genetic tests (see Table 3
for the details of dichotomization).
The model building strategy suggested by Hosmer and Lemeshow
(2000) was used and included the following steps: (a) univariateanalysis of each variable and inclusion if the p-value was lower than
0.25; (b) backward elimination of each variable that did not
contribute to the model on the ground of the Likelihood Ratio Test
using a cut-off of 0.05 level of signiﬁcance; variables whose exclusion
markedly altered the coefﬁcient of the remaining variables were kept
in themodel; (c) testing of interaction terms using a cut-off of 0.15 level
of signiﬁcance. Adjusted odds ratio (OR) and 95% conﬁdence intervals
(CI) were calculated. All statistical calculations were performed using
Stata version 8.0 (College Station, Texas, Stata Corporation, 2003).
Results
Study population
Of the original sample of 1670 physicians, 120 were ineligible
because they were retired or no longer in clinical practice. The ﬁnal
sample size included 1550 physicians, of which 1079 responded
(overall response rate: 69.6%). Responders and non-responders were
comparable in terms of demographic characteristics (location, gender,
and age; p N 0.05). Most responding physicians were from Rome
(73.8% of responders vs. 76.9% of non-responders) and male (56.2%
of responders vs. 58.9% of non-responders), with a mean age of 50.7
(±11.5) years (50.0 years for non-responders). The demographic
characteristics of the sample were similar to those of all Italian physi-
cians, as 60.6% of the members of the National Board of Physicians are
male and have a similar age distribution (ENPAM, 2012). Other demo-
graphics, professional and personal characteristics of the responding
physicians are listed in Table 1.
Knowledge
Italian physicians' knowledge of predictive genetic testing for can-
cer appeared adequate in terms of BRCA1/BRCA2 testing, although
knowledge of APC testing was lacking [Table 2(A)]. Almost half of
the sample (42.8%) answered all three questions about BRCA1/2
testing correctly. This knowledge was improved if physicians were
exposed to cancer genetic testing during graduate or postgraduate
training, andwith the increase in the amount of time dedicated to con-
tinuing medical education. Female physicians were more likely to
have adequate knowledge about BRCA1/2 testing, and this knowledge
increased if genetic testing laboratories were located in the same geo-
graphical area as the physicians' workplace (Model 1 in Table 3). Only
16.9% of physicians provided correct answers to all three questions
about APC testing. This knowledge, as in the previous case, increased
with exposure to cancer genetic testing during graduate and post-
graduate training and with the amount of time dedicated to continu-
ing medical education (Model 2 in Table 3).
Physicians' knowledge was satisfactory on the penetrance of BRCA1/
BRCA2mutations, but not regarding the prevalence of hereditary breast
cancer. Most physicians knew that the absolute risk of developing
breast cancer in the presence of BRCA1/BRCA2 mutations is 40–80%,
but less than one third recognized that the percentage of breast cancer
cases associated with BRCA1/BRCA2mutations is 1–10% [Table 2(B)]. By
contrast, knowledge concerning inherited forms of colorectal cancer
was inadequate, as none of the surveyed physicians knew that the per-
centage of colorectal cancer cases associated with APCmutations is less
than 5%, and only a small proportion of physicians recognized that the
absolute risk of developing cancer in the presence of APC mutations is
100% [Table 2(B)].
Attitudes
Attitudes toward predictive genetic testing for breast and colorec-
tal cancer were quite heterogeneous (Table 4). Although nearly all
physicians agreed that predictive genetic testing increases the chances
of prevention, only aminority appeared to accept that the principles of
Table 1
Demographics and professional and personal characteristics of the responding physi-
cians. Italy, 2010.
Variables n (%)
Location (1079)a
Florence 283 (26.2)
Rome 796 (73.8)
Gender (1071) a
Female 469 (43.8)
Male 602 (56.2)
Age, years (1015) a
b30 65 (6.4)
31–40 151 (14.9)
41–50 208 (20.5)
51–60 419 (41.3)
≥61 172 (16.9)
Exposure to cancer genetic testing during graduate
training (1008) a
No 803 (79.7)
Yes 205 (20.3)
Exposure to cancer genetic testing during postgraduate
training (1009) a
No 795 (78.8)
Yes 214 (21.2)
Postgraduate training courses about epidemiology
and EBM (1007) a
No 617 (61.3)
Yes 390 (38.7)
English language knowledge (1010) a
Very low 113 (11.2)
Low 232 (23.0)
Intermediate 349 (34.5)
Good 221 (21.9)
Excellent 95 (9.4)
Internet available in the workplace (1004) a
No 89 (8.9)
Yes 915 (91.1)
Hours per week dedicated to continuing medical
education (890) a
b1 0 (0)
1–5 677 (76.1)
6–10 147 (16.5)
N10 66 (7.4)
Average number of patients treated in a typical
week (1011) a
1–20 396 (39.2)
21–40 235 (23.2)
41–60 149 (14.7)
N60 231 (22.9)
Patient requests for cancer genetic tests in the previous
year (1006) a
No 829 (82.4)
Yes 177 (17.6)
Presence of genetic testing laboratories in the geographical
area of professional activity (1000) a
No 505 (50.5)
Yes 495 (49.5)
Personal or family history of breast cancer (1011) a
No 778 (76.9)
Yes 233 (23.1)
Personal or family history of colorectal cancer (1009) a
No 760 (75.3)
Yes 249 (24.7)
Ordering or referring patients for breast cancer predictive
genetic testing in the previous 2 years (1007)a
No 906 (90.0)
Yes 101 (10.0)
Ordering or referring patients for colorectal cancer
predictive genetic testing in the previous 2 years (1004)a
No 957 (95.3)
Yes 47 (4.7)
a Number of physicians responding to the question.
Table 2
Knowledge of the responding physicians regarding: (A) predictive genetic testing for
breast and colorectal cancer (BRCA1/2 and APC testing); (B) prevalence of hereditary
forms of breast and colorectal cancer and penetrance of BRCA1/2 and APC mutations.
Italy, 2010.
(A) Knowledge of predictive genetic testing
for breast and colorectal cancer
Agree,
n (%)
Uncertain,
n (%)
Disagree,
n (%)
Predictive genetic tests for BRCA1/BRCA2
mutations are able to identify patients at
high risk to develop breast cancer (848)a
622 (73.3) 226 (26.7) 0
Women with breast cancer and strong
family history should perform
BRCA1/BRCA2 testing (838) a
633 (75.5) 154 (18.4) 51 (6.1)
Scientiﬁc evidence recommends for
BRCA1/BRCA2 positive women clinical and
instrumental surveillance starting from the
age of 25 (839) a
699 (83.3) 124 (14.8) 16 (1.9)
Predictive genetic tests for APCmutations are
able to identify patients who will develop
colorectal carcinoma (856) a
571 (66.7) 246 (28.7) 39 (4.6)
APC testing is recommended for 10–12 years
old children with a ﬁrst grade relative with
known APC mutation (780) a
337 (43.2) 339 (43.5) 104 (13.3)
Scientiﬁc evidence recommends for APC
positive individuals periodic colonoscopy,
starting from the age of 10–15 (809) a
325 (40.2) 353 (43.6) 131 (16.2)
(B) Knowledge of the prevalence of hereditary forms of breast and
colorectal cancer and penetrance of BRCA1/2 and APC mutations
n (%)
The percentage of breast cancer cases associated with BRCA1/2
mutations is (766)a:
1–10% 230 (30.0)
15–35% 387 (50.5)
N50% 149 (19.5)
The absolute risk of developing breast cancer in the presence
of BRCA1/2 mutations is (599)a:
b10% 0
40–80% 568 (94.8)
100% 31 (5.2)
The percentage of colorectal cancer cases associated with
APC mutations is (587)a:
b5% 0
10–25% 386 (65.8)
N40% 201 (34.2)
The absolute risk of developing colorectal cancer in the presence
of APC mutations is (583)a:
b10% 0
40–80% 515 (88.3)
100% 68 (11.7)
Note: Number and percentages referring to correct answers are in bold.
a Number of physicians responding to the question.
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netic tests to be delivered to the general population. Most physicians
agreed on the importance of evidence-based guidelines, genetic
counseling, and the ethical, legal and social implications of predictivegenetic testing. A total of 23.8% of physicians showed a positive attitude
in at least 70% of the questions, and this dichotomizationwas arbitrarily
used to identify predictors of a positive attitude. Signiﬁcant predictors
of positive attitudes included the following: (a) exposure to cancer ge-
netic tests during graduate training and attendance at postgraduate
training courses in epidemiology and EBM, and (b) no patient requests
for cancer genetic tests in the previous year and presence of genetic
testing laboratories in the local area. Female physicians weremore like-
ly to show positive attitudes, as were physicians with an adequate
knowledge of predictive genetic testing for both breast and colorectal
cancers (Model 3 in Table 3).
Professional behavior
Few physicians in our sample had either referred patients for or
ordered predictive genetic testing for breast (10.0%) or colorectal can-
cer (4.7%) in the previous 2 years. The main determinant of profes-
sional use was the patient requests for genetic testing (Models 4 and
5 in Table 3). Other signiﬁcant determinants included the following:
(a) adequate knowledge of the professional use of predictive genetic
testing for breast cancer (Model 4 in Table 3), and (b) the number
Table 3
Determinants of physicians knowledge, attitudes and professional behavior concerning predictive genetic testing for cancer. Italy, 2010.
Variables OR 95% CI
Model 1: Knowledge about predictive genetic testing for breast cancer (BRCA1/BRCA2 mutations).a
Gender (female = 0; male = 1) 0.72 0.54–0.95
Hours per week dedicated to continuing medical education (b1 = 0; 1–5 = 1; 6–10 = 2; N10 = 3)b 1.50 1.18–1.90
Exposure to cancer genetic tests during graduate training (No = 0; Yes = 1) 2.33 1.59–3.40
Exposure to cancer genetic tests during postgraduate training (No = 0; Yes = 1) 1.59 1.10–2.29
Presence of genetic testing laboratories in the geographical area of professional activity (No = 0; Yes = 1) 1.38 1.04–1.83
Model 2: Knowledge about predictive genetic testing for colorectal cancer (APC mutations).c
Hours per week dedicated to continuing medical education (b1 = 0; 1–5 = 1; 6–10 = 2; N10 = 3)b 1.53 1.18–1.98
Exposure to cancer genetic tests during graduate training (No = 0; Yes = 1) 1.67 1.09–2.56
Exposure to cancer genetic tests during postgraduate training (No = 0; Yes = 1) 1.74 1.14–2.64
Model 3: Attitudes towards predictive genetic testing for breast and colorectal cancer.d
Gender (female = 0; male = 1) 0.54 0.40–0.71
Exposure to cancer genetic tests during graduate training (No = 0; Yes = 1) 1.87 1.30–2.69
Postgraduate training courses about epidemiology and EBM (No = 0; Yes = 1) 1.71 1.28–2.28
Patient request of cancer genetic tests in the previous year (No = 0; Yes = 1) 0.64 0.44–0.93
Presence of genetic testing laboratories in the geographical area of professional activity (No = 0; Yes = 1) 1.41 1.06–1.88
Knowledge about predictive genetic testing for breast and colorectal cancer (Not adequate = 0; adequate = 1)e 1.66 1.11–2.48
Model 4: Professional use of predictive genetic testing for breast cancerf
Patient request of cancer genetic tests in the previous year (No = 0; Yes = 1) 12.65 7.77–20.59
Knowledge about predictive genetic testing for breast cancer (Not adequate = 0; adequate = 1)a 3.21 1.92–5.36
Model 5: Professional use of predictive genetic testing for colorectal cancerg
Hours per week dedicated to continuing medical education (b1 = 0; 1–5 = 1; 6–10 = 2; N10 = 3)b 1.99 1.30–3.05
Patient request of cancer genetic tests in the previous year (No = 0; Yes = 1) 7.02 3.61–13.64
Presence of genetic testing laboratories in the geographical area of professional activity (No = 0; Yes = 1) 2.05 1.01–4.21
Attitudes (Negative = 0; positive = 1)d 2.17 1.12–4.23
Note: OR: Odds Ratio. CI: Conﬁdence Interval.
a Physicians were classiﬁed as those who answered correctly to all three questions on predictive genetic testing for breast cancer [ﬁrst three questions in Table 2(A)] vs. all others.
b Variable modeled as ordinal because linearity was assessed.
c Physicians were classiﬁed as those who answered correctly to all three questions on predictive genetic testing for colorectal cancer [last three questions in Table 2(A)] vs. all
others.
d Physicians were divided into those who showed positive attitudes in at least 70% of the questions (at least ﬁve of the seven questions listed in Table 4) vs. all others.
e Physicians were classiﬁed as those who answered correctly to all six questions on predictive genetic testing for breast and colorectal cancers [Table 2(A)].
f Physicians who referred patients for or ordered predictive genetic tests for breast cancer in the previous 2 years were grouped vs. all others.
g Physicians who referred patients for or ordered predictive genetic tests for colorectal cancer in the previous 2 years were grouped vs. all others.
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presence of genetic testing laboratories locally, and positive attitudes
about the professional use of predictive genetic testing for colorectal
cancer (Model 5 in Table 3). It is interesting to note that when ordering
or referring patients to predictive genetic testing for cancer for patients,
almost all physicians agreed upon the importance of collecting informa-
tion about the family (99.6%) and personal history of cancer (98.0%) and
the importance of genetic counseling (91.8%) (data not shown).
Approximately 80% of the physicians considered their knowledge
of the appropriate use of predictive genetic testing for cancer to be
inadequate; almost all of the physicians (94.2%) believed that theirTable 4
Attitudes of the responding physicians towards predictive genetic testing for breast and co
Predictive genetic tests for breast and colorectal cancer increase the prevention opportun
Predictive genetic tests able to identify an increased risk of developing breast or colorect
if there are no preventive and/or curative interventions of proven efﬁcacy (882)a
Predictive genetic tests for breast or colorectal cancer should be performed only if econo
ratios favorable compared to alternative health interventions (898) a
Authoritative and evidence-based guidelines are needed for the appropriate use of predic
cancer (931) a
Predictive genetic tests for breast and colorectal cancer should be performed without gen
beneﬁts and risks of the tests (919) a
Predictive genetic tests for breast and colorectal cancer can contribute efﬁcaciously to he
if included in wider strategies taking into account the other available health interventi
The implementation of predictive genetic tests for breast and colorectal cancer, being a m
ethical, legal and social implications (922) a
Note: Number and percentages referring to answers denoting a positive attitude are in bol
a Number of physicians responding to the question.knowledge should be improved, and 86.0% believed that speciﬁc
post-training courses in predictive genetic testing for cancer are
needed (data not shown).
Discussion
Most surveys reported in the literature reveal a lack of knowledge
regarding predictive genetic testing for cancer among physicians
(Acton et al., 2000; Batra et al., 2002; Bellcross et al., 2011; Escher
and Sappino, 2000; Klitzman et al., 2012; Nippert et al., 2011;
Pichert et al., 2003; Wideroff et al., 2005; Wilkins-Haug et al., 2000).lorectal cancer.
Agree,
n (%)
Uncertain,
n (%)
Disagree,
n (%)
ities (913)a 771 (84.4) 124 (13.6) 18 (2.0)
al cancer should be performed even 343 (38.9) 284 (32.2) 255 (28.9)
mical evaluations show cost-effectiveness 387 (43.1) 258 (28.7) 253 (28.2)
tive genetic tests for breast and colorectal 875 (94.0) 56 (6.0) 0
etic counseling informing patients of the 125 (13.6) 159 (17.3) 635 (69.1)
alth promotion and cancer prevention only
ons (914) a
806 (88.2) 83 (9.1) 25 (2.7)
edical matter, should not take into account 255 (27.7) 160 (17.3) 507 (55.0)
d.
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the prevalence of inherited forms of breast and colorectal cancer and
the penetrance of APCmutations. These results have important practi-
cal implications because overestimating the prevalence of inherited
forms of breast and colorectal cancer may result in the inappropriate
and unnecessary use of predictive genetic tests. Conversely, if physi-
cians underestimate the penetrance of the APC mutations, they may
be less inclined to advise family members about the inherited risks,
or less likely to refer patients to clinics that could provide optimum
care. It is interesting to note that the items concerning education in
the current survey were among the most important determinants of
good knowledge of predictive genetic testing, conﬁrming that educa-
tion and speciﬁc training are fundamental issues that need to be
addressed.
Physicians' attitudes usually have a vital impact on the process of
technology diffusion. Many Italian physicians believed that predictive
genetic testing for cancer should be performed without clear scientif-
ic evidence regarding the efﬁcacy and cost-effectiveness of such inter-
ventions. These beliefs are in line with the ﬁndings obtained in more
general terms by other Italian surveys (De Vito et al., 2009a, 2009b)
and represent an obstacle to the appropriate use of predictive genetic
tests because they are often introduced into clinical practice for
commercial purposes, in the absence of rigorous evaluation of efﬁcacy
and cost-effectiveness (Col, 2003; EASAC and FEAM, 2012). Items
concerning education and adequate knowledge had a positive impact
on attitudes. The availability of local genetic testing laboratories in-
creased the likelihood of a positive attitude. Unexpectedly, patient in-
quiries about cancer genetic testing during the previous year
appeared to have a negative effect on attitudes. Female physicians
were more likely to have a positive attitude (and adequate knowl-
edge) than males, and this is in line with a greater attention of the fe-
male gender to predictive genetic testing for cancer ascertained in
other surveys (Escher and Sappino, 2000; Geller and Holtzman,
1995; Wertz, 1993).
Concerning professional use of predictive genetic testing for can-
cer, approximately 10% of physicians declared that they had referred
patients for or ordered predictive genetic testing for breast cancer (5%
for tests for colorectal cancer) in the previous 2 years. These ﬁgures
are similar to, or somewhat lower than, those reported in others sur-
veys (Acton et al., 2000; Bellcross et al., 2011; Klitzman et al., 2012;
Mehnert et al., 2003; Shields et al., 2008; Sifri et al., 2003;
Welkenhuysen and Evers-Kiebooms, 2002; Wideroff et al., 2003).
Even if nearly all the physicians acknowledged both the importance
of collecting information regarding a familial and personal history of
cancer and of genetic counseling in prescribing or referring patients
for predictive genetic testing, the current survey was not designed
to investigate whether the professional use of the tests was appropri-
ate. The factors most strongly related to physicians' use of predictive
genetic tests for cancer were patient requests during the previous
year and, to a lesser extent, the presence of local genetic testing lab-
oratories locally. Adequate knowledge, positive attitudes, and time
spent for continuing medical education also had an impact on the
likelihood of professional use. The importance of patient inquiries
has been reported in the literature (Klitzman et al., 2012; Sifri et al.,
2003; White et al., 2008; Wideroff et al., 2003). In the current survey,
physicians caring for patients who asked for cancer predictive genetic
testing during the past year reported a 13-fold and 7-fold greater use
of tests for breast and colorectal cancer, respectively. The fact that the
physicians' use of genetic tests appears to be guided, at least in part,
by patient requests suggests that their decisions may be driven by
factors other than clinical indications or clinical utility. These ﬁndings
underscore the importance of the physician being ready to respond to
patient requests for testing by providing patients with information
about the advantages and limitations of such tests in addition to offer-
ing genetic counseling when appropriate or suggesting other alterna-
tives when testing is not indicated.This study has several limitations. First, a high percentage of
non-responders (approximately 20%) was registered for questions
concerning knowledge. Therefore, knowledge estimates reported in
this study (calculated on responders) may be overestimated because
non-responders may be less informed. Second, because information
about specialties was not available from the registries of the Italian
Boards of Physicians, the survey could not be designed to assess
the likely differences that may exist across specialties. Although
physicians were queried about their specialty in the questionnaire,
the number of physicians in most specialties was too low to perform
meaningful comparisons, therefore, the variable “specialty” was
not included in the analyses. Finally, because a clear need to slim
down the questionnaire emerged in the pilot study, only questions
concerning APC gene mutations were included in the knowledge
items concerning inherited forms of colorectal cancer, and questions
on other gene mutations (e.g., for Lynch syndrome) were not includ-
ed. APCmutations are less frequent but occurwith a higher penetrance
than other gene mutations. Previous surveys in the U.S. showed that
physician's awareness of commercial availability was higher for APC
tests than for tests for genes associated with Lynch syndrome (Batra
et al., 2002; Wideroff et al., 2003). However, it should be acknowl-
edged that there are no data available in the Italian context to
conclude if knowledge about APC tests is equal or different from
knowledge about tests for genes associated with Lynch syndrome.
Conclusions
The results of this survey indicate that physicians in Italy are not
yet ready to play a deﬁnitive, appropriate role in the context of cancer
genetic predictive testing. Many survey items related to education
had a positive inﬂuence on knowledge, attitudes and, to a lesser ex-
tent, professional use. The professional use of cancer predictive genet-
ic tests in Italy might be not completely appropriate, and physicians
reported a high level of interest in receiving additional speciﬁc train-
ing in the ﬁeld. Overall, this study clearly indicates that priority must
be given to targeted educational programs (Mazzucco et al., 2012).
However, lessons drawn from many other areas of medicine indicate
that education alone may not translate into the effective and appro-
priate adoption of innovative practices (Greco and Eisenberg, 1993;
Grol and Grimshaw, 2003). A speciﬁc policy regarding public health
genomics needs to be developed at the national level, which is
currently being undertaken in Italy by the Ministry of Health (Simone
et al., 2013). Additional research is needed to characterize further the
contextual factors that inﬂuence the incorporation of cancer predictive
genetic testing into clinical practice, and the organizational changes
needed within the health care system to provide these services both
effectively and efﬁciently.
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